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Delusional infestation is a relatively rare disorder characterised by the 
belief of being infested with living or non-living organisms [1]. Classically, 
patients present with the belief that they have these organisms on or 
underneath their skin but many other presentations are possible 
including beliefs of an infestation of the patient’s immediate 
environment or organs other than the skin. The illness is usually classed 
as a mono-delusional disorder and shared delusional beliefs as well as 
delusions by proxy are possible [2]. The imaginary pathogens have 
changed over time but insects and worms are still the most common. 
Non-living pathogens have increasingly been named by patients as the 
cause for their symptoms such as fibers or threads coming out of their 
skin [1]. The most recent study suggests that a quarter of patients are 
now presenting with non-living pathogens [3]. Delusional infestation can 
be primary as well as secondary. As a primary delusional disorder it 
meets criteria of a persistent delusional disorder in ICD 10 (code F22) or 
a delusional disorder somatic type in DSM- IV-TR (code 297.1) As a 
secondary phenomenon it is associated with a number of illnesses: 
mental illnesses such as schizophrenia, dementia and depression, 
medical illnesses such as diabetes, certain cancers that can cause 
pruritus, stroke and substance misuse particularly with stimulants. 
Prescribed medication which can frequently cause pruritogenic or 
dermatological adverse events such as erythema, itch and rashes can 
also cause secondary delusion infestation [1].  
 
Dermatologists are usually often the first specialist patients with DI get 
referred to [1], because dermatological symptoms are common in DI and 
often the main complaint. A survey amongst UK dermatologists showed 
that most had seen DI patients in the last 3 years and half had at least 
one current open case [6]. Referrals to psychiatry are usually rejected by 
patients on the basis that they do not think they have a mental illness 
[1]. Treatment suggestions have been made to allow dermatologists to 
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effectively treat DI patients in their clinics [7,8] rather than loosing the 
patient to any treatment by insisting on the patient’s engagement with 
psychiatric services. 
 
It has been well described in the literature that the use of cocaine and 
other stimulants can cause acute symptoms of delusional infestation. In 
the past this has been called “cocaine bugs”, however, there is a long list 
of prescribed and non- prescribed medications and substances that have 
been implicated with delusional infestation including amphetamines, 
cannabis, codeine, certain antibiotics and non-steroidal anti-
inflammatory drugs to name but a few.  
Little is known about the prevalence of substance use in patients with 
delusional infestation. In a small pilot study, Bewley et al recently found 
the prevalence of illegal drug use to be higher on drug tests than 
admitted by patients, suggesting a possible under-reporting of drug use 
by patients who present with delusional infestation to specialist clinics 
[ref]. It is not known whether the prevalence of illegal substances is 
more common in the population that presents with delusional 
infestation compared to the normal population. The prevalence of illegal 
drug use is relatively well known in many countries. In Germany for 
example the life time prevalence of any illegal drug use is 25% with less 
than 5% having consumed any illegal drug in the last 30 days. 
Dependence or harmful use of cannabis is estimated at 0.5% of German 
adults, with 0.2% estimated to be addicted to cocaine, 0.1% to 
amphetamines and a slightly higher number showing signs of harmful 
use of amphetamines [http://www.drogenbeauftragte.de/drogen-und-
sucht/illegale-drogen/heroin-und-andere-drogen/situation-in-
deutschland.html]. The World Health Organisation has published 
substance misuse data for the population aged 15 to 64 using the best 
available data for each country. The population prevalence for illegal 
and prescribed opiate use in this group is estimated at 0.32% in 
Germany, 0.16% in the Netherlands, 5.4% in the United States, and 
0.75% in England and Wales. For amphetamines and prescription 
stimulants the prevalence is estimated at 0.7% in England and Wales, 
0.4% in the Netherlands, 1.9% in the United States, and 0.7% in 
Germany. For cocaine the prevalence is estimated at 0.8% in Germany, 
1.2% in the Netherlands, 2.1% in the United States, and 2% in England 
and Wales. Cannabis use is estimated at 4.5% in Germany, 7% in the 
Netherlands, 15.4% in the United States, and 6.4% in England and Wales. 
The World Health Organisation data 
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[http://www.unodc.org/wdr2015/en/maps-and-graphs.html] normally 
uses the best available and most recent studies from each of these 
countries. We used the best and most recent quoted. Updates are not as 
regular as for example the updates of the German Health Ministry 
quoted above. Most UN data used in this introduction are from 2009-
2013. 
 
In our study we use data from consecutive patients attending specialist 
clinics in England, Germany (Berlin) and the Netherlands. We also report 
data from non-consecutive patients from Germany (Ulm, semi-urban) 
and from Austin, US. The aim of the study is to estimate the prevalence 






Few specialist clinics exist worldwide for the treatment of delusional 
infestation. Not all of those clinics test their patients regularly for the 
use of illegal substances. We have examined a cohort of patients from 
four centres where consecutive patients have been tested with a urine 
drugs screen for the use of cocaine, amphetamines, benzodiazepines, 
cannabis, opioids and methadone. We collected basic demographic data 
including the sex and age of the patient as well as information about 
whether the result could be explained by prescribed medication. This 
has generated prevalence data for each of the substances.  
 
The centres included were: a psycho-dermatology clinic in London led by 
a dermatologist and a psychiatrist, a clinic in Liverpool led by a 
consultant of tropical medication and a psychiatrist, a centre in Berlin 
led by a dermatologist with access to psychiatric liaison and one clinic in 
Amsterdam led by a dermatologist with access to psychiatric liaison. All 
of these clinics are tertiary referral centres and accept referrals from a 
wide geographical area. All centres are free of cost to the patients at the 
point of presentation. In addition, we present non-consecutive patient 
data from a clinic in Ulm, Germany led by a psychiatrist with a special 
interest in delusional infestation and from a dermatologist-led specialist 





Plain frequencies and cross-tabulations regarding the prevalence of drug 
use either prescribed or not, were calculated across age, age categories, 
gender and sites. Differences in age were tested by means of t-test; the 
differences across age categories, gender and sites were tested by 
means of chi-square statistics. Cannabis and benzodiazepines were 
categorized as soft drugs, amphetamines, cocaine, opiates and 




Table 1 presents patient characteristics and frequencies of drug use in 
the consecutive European and the non-consecutive US sample. Table 2 
presents the differences of drug use across age categories, gender and 
sites, whereas table 3 describes the differences between these groups in 
more detail, per drug and with drugs classed into soft and hard drugs for 
the consecutive sample.  
 
Table 1 about here.  
 
We had 92 patients in the main consecutive sample the mean age of the 
patients was 55.6 years (sd=15.9), most patients (59%, n=55) were 
female. 44 (48%) of the patients were seen in London, 10 (11%) in 
Liverpool, 16 (17%) in Amsterdam and 22 (24%) in Berlin. 28 patients 
(30%) tested positive for one drug or another. In 6 cases the positive 
drug result was explained by prescription medication. This was 
prescribed benzodiazepines in 5 cases, in one case it was prescribed 
amfetamines for ADHD. Amphetamines and Cannabis were the most 
used drugs. In 4 cases patients used both. Benzodiazepines were used by 
5 patients.  
 
The other drugs were used less often. Cocaine and methadone were 
used by one patient, and opiates by two patients. The patient using 
methadone combined this with the use of benzodiazepine on 
prescription.   
 
When we relate drug use to the main patient characteristics, we observe 
that younger patients are more likely to use drugs, as well as a larger 
number of drugs. This was primarily amphetamines and cannabis. Men 
were significantly more likely to test positive for drugs than women. 
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Drug use was highest in the Amsterdam clinic, followed by the Liverpool 
and London sites. It was significantly lower in the Berlin clinic.  
 
Table 2 and Table 3 about here.  
 
Results from the Ulm site, Germany: a psychiatrist with a specialist 
interest in the University hospital in Ulm found 8 drug screens 
performed on 25 patients. 1 was positive for cannabis with a high 
alcohol level of 2.9 g/l (male, 38 years old). 1 patient tested positive for 
benzodiazepines which were prescribed (72 year old female). The other 
results were negative. 
Results from the Austin site: In a dermatologist-led specialist clinic in 
Austin, Texas, we have 92 non consecutive samples. Patients would be 
referred or self-present and have to pay for services. The Austin data 
show a very different picture compared to the European sample and 
compared to drug use statistics in the United States. 40% of the patients 
tested in Austin were positive for any drug. 50-65 year old patients 
showed the highest level of drug use (42%), followed by over 65 year 
olds (34%) and under 50 year olds (24%). Patients with positive results 
were on average older (mean age 57 versus 52 for no drug use). These 
differences were not statistically significant. 83% of females tested 
positive for any drug compared to only 17% of males (p=0.042). The 
majority of patients tested positive for two drugs compared to only one 
in the European sample. Only 9 out of all positive drug results could not 
be explained by prescribed medication. It is very clear that this sample is 
not representative of drug use in the US. Patients in the US have to pay 
for a toxicology screen and positive results may have consequences for 
their insurance cover. It is therefore unlikely that patients agree to drug 
testing that showed significant illegal drug use. When we compared the 
two samples statistically, they were not similar and therefore could not 







Our cohort study of 92 consecutive patients seen for delusion infestation 
in specialist settings shows the typical distribution for DI of female 
predominance and more elderly patients [1]. 30% of our consecutive 
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patients were tested positive for any tested substance. 13% tested 
positive for amphetamines and cannabis respectively, followed by 8% 
who tested positive for benzodiazepines, 4% for opiates and 1% for 
cocaine and methadone respectively. This is much more than what we 
would expect to find in the normal population. The reasons for this are 
not immediately obvious. One explanation is that drug induced 
delusional infestation is still a common phenomenon whose prevalence 
is under-estimated. Another explanation may be that patients with 
symptoms of delusional infestation take illicit substances in the hope to 
relieve their distress. Escamilla et al showed that patients with delusions 
of infestation were more likely to use narcotics than other dermatologic 
patients with chronic pruritic skin conditions [5]. This may indicate an 
attempt to self-medicate. 
In keeping with the normal population data, men and younger were 
more likely to use illicit substances than women and older patients. The 
much higher rate of substance use has important implications for 
specialists who see DI patients. Careful exploration of drug use, routine 
drug testing whenever possible, and an increased awareness of the 
possibility of illicit drug use are obvious consequences of these findings. 
Awareness of the possibility of drug use should rise, even when initially 
unexpected.  
It is not clear why DI patients in Amsterdam are much more likely to test 
positive for drugs than in London, Liverpool or Berlin. Illegal drugs are 
widely available in all 4 cities. However, our samples are relatively small. 
There is a possibility that referrals are processed differently and patients 
in Amsterdam may undergo fewer investigations before being seen in 
the DI clinic. Ultimately, we would need bigger sample sizes to confirm 
this finding and more qualitative research to examine the reasons 
behind it. We also have to consider that our drug screens have a short 
window to detect drug use, with the exception of cannabis it is less than 
4 days. Depending on the day the urine sample was obtained (close after 
a weekend, early versus late in the diagnostic evaluation) the results 
may vary.  
In the United States it is likely that considerations about payment and 
consequences for insurance cover are likely to deter patients from 
agreeing to toxicology screens, especially when they know that the 
screen will test positive for substances that are not prescribed. It is also 
possible that despite our best efforts to detect a dermatological 
diagnosis, some of the patients diagnosed with DI had other secondary 
medical or psychiatric problems [4]. Since DI is a diagnosis of exclusion, 
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there is a small possibility for this to affect our data. The high number of 
older patients with prescribed illicit substances may indicate this to be a 
possibility in the Austin sample.  
 
The important aspect for dermatologists is to think of drug use, ask 
questions about current and past use, and ask the patient for a urine 
sample in order to get a toxicological screen. Patients who refuse should 
be assumed to possibly take drugs. Because illicit substances, especially 
stimulants, are a major trigger factor for delusional infestation, patients 
need to be made aware of this link and encouraged to stop their drug 
use to see whether that improves their symptoms without the use of 
additional medication. This may require a referral to local substance 
misuse services if patients struggle to stop their illicit drug use by 
themselves.  
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Table 1:  Frequencies of patient characteristic and drug use 
 
  Europe  Austin USA 
 N=    
Total  
 













Any drug use 
One drug 















































































































































































Table 2:  Any Drug use compared to background characteristics 
(European sample only) 
 
 N= No drug use Any drug use p 
Europe 92    
































































Table 3 Age, age category, gender and site related to drug use 













































































N= 92 17 12 7 16 12 1 4 1 
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